Aduro Biotech, Inc. today announced that it has received a milestone payment from Janssen Biotech, Inc. for the acceptance of an Investigational New Drug Application by the U.S. Food and Drug Administration for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. Janssen, Aduro’s license partner for ADU-741, plans to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 by the end of 2015.
